Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome.
Davide LeardiniFrancesco VenturelliFrancesco BaccelliSara CerasiEdoardo MuratorePatrizia BrigidiAndrea PessionArcangelo PreteRiccardo MasettiPublished in: International journal of molecular sciences (2022)
The gut microbiome (GM) has emerged in the last few years as a main character in several diseases. In pediatric oncological patients, GM has a role in promoting the disease, modulating the effectiveness of therapies, and determining the clinical outcomes. The therapeutic course for most pediatric cancer influences the GM due to dietary modifications and several administrated drugs, including chemotherapies, antibiotics and immunosuppressants. Interestingly, increasing evidence is uncovering a role of the GM on drug pharmacokinetics and pharmacodynamics, defining a bidirectional relationship. Indeed, the pediatric setting presents some contrasts with respect to the adult, since the GM undergoes a constant multifactorial evolution during childhood following external stimuli (such as diet modification during weaning). In this review, we aim to summarize the available evidence of pharmacomicrobiomics in pediatric oncology.
Keyphrases
- end stage renal disease
- palliative care
- systematic review
- randomized controlled trial
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prostate cancer
- squamous cell carcinoma
- peritoneal dialysis
- prognostic factors
- young adults
- mechanical ventilation
- papillary thyroid
- extracorporeal membrane oxygenation
- electronic health record
- radical prostatectomy